HC Wainwright reiterated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $14.00 price target on the stock.
Evaxion Biotech A/S Trading Up 1.9 %
Shares of EVAX opened at $2.64 on Friday. Evaxion Biotech A/S has a 1 year low of $2.26 and a 1 year high of $13.61. The stock’s 50-day moving average price is $2.95 and its two-hundred day moving average price is $3.18. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00.
Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. The firm had revenue of $3.02 million during the quarter, compared to the consensus estimate of $0.19 million. Equities analysts expect that Evaxion Biotech A/S will post -0.24 EPS for the current year.
Institutional Inflows and Outflows
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Read More
- Five stocks we like better than Evaxion Biotech A/S
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Intel: Is Now the Time to Be Brave?Â
- Why Are These Companies Considered Blue Chips?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Overbought Stocks Explained: Should You Trade Them?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.